Cargando…

Safety, tolerability and clinical implementation of ‘ready-to-use’ (68)gallium-DOTA0-Tyr3-octreotide ((68)Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

BACKGROUND: (68)Ga-DOTA0-Tyr3-octreotide ((68)Ga-DOTATOC) positron emission tomography–CT (PET-CT) has superior diagnostic performance compared to the licensed tracer OctreoScan single photon emission CT–CT in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). A new preparation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manoharan, Prakash, Lamarca, Angela, Navalkissoor, Shaunak, Calero, Jose, Chan, Pei San, Julyan, Peter, Sierra, Maribel, Caplin, Martyn, Valle, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078687/ https://www.ncbi.nlm.nih.gov/pubmed/32188715 http://dx.doi.org/10.1136/esmoopen-2019-000650

Ejemplares similares

68Ga-DOTA-D Phe1-Tyr3-Octreotide (DOTATOC)-PET/CT in a Suspected Case of Recurrent Meningioma
por: Jain, Sachin, et al.
Publicado: (2017)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

[(68)Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [(177)Lu]DOTATOC PRRT: The “Theragnomics” Concept
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Occupational radiation exposure assessment during the management of [(68)Ga]Ga-DOTA-TOC
por: Riveira-Martin, Mercedes, et al.
Publicado: (2022)

Difficult diagnosis and localization of focal nesidioblastosis: clinical implications of (68)Gallium-DOTA-D-Phe(1)-Tyr(3)-octreotide PET scanning
por: Kim, Jae Ri, et al.
Publicado: (2016)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

Hypoglycemia-Triggered Motion Artifact on (68)Ga-DOTA-TOC Positron Emission Tomography/Computed Tomography
por: Chandra, Piyush, et al.
Publicado: (2021)

Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours
por: Kim, Yong-il, et al.
Publicado: (2020)

Impact of segmentation and discretization on radiomic features in (68)Ga-DOTA-TOC PET/CT images of neuroendocrine tumor
por: Liberini, Virginia, et al.
Publicado: (2021)

Validation of Quality Control Parameters of Cassette-Based Gallium-68-DOTA-Tyr3-Octreotate Synthesis
por: Sammartano, Antonino, et al.
Publicado: (2020)

The utility of gallium-68 DOTATOC PET/CT in lymphangioleiomyomatosis
por: Gaffney, Brian, et al.
Publicado: (2021)

Monte Carlo investigation of PET [(68)Ga]Ga-DOTA-TOC activity-administration protocols for consistent image quality
por: Kalaitzidis, Philip, et al.
Publicado: (2023)

Meningiomas: A Comparative Study of (68)Ga-DOTATOC, (68)Ga-DOTANOC and (68)Ga-DOTATATE for Molecular Imaging in Mice
por: Soto-Montenegro, María Luisa, et al.
Publicado: (2014)

[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
por: Baum, Richard P., et al.
Publicado: (2016)

Failure of functional imaging with gallium-68-DOTA-D-Phe1-Tyr3-octreotide positron emission tomography to localize the site of ectopic adrenocorticotropic hormone secretion: a case report
por: Gani, Linsey U, et al.
Publicado: (2011)

Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate
por: Ma, Michelle T., et al.
Publicado: (2015)

Dual [(68)Ga]DOTATATE and [(18)F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
por: Chan, David L., et al.
Publicado: (2022)

Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Impact of (68)Ga-DOTATOC PET/CT in comparison to (111)In-Octreotide SPECT/CT in management of neuro-endocrine tumors: A case report
por: Tolomeo, Anna, et al.
Publicado: (2020)

Comparison of [(18)F]DOPA and [(68)Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
por: Veenstra, Emile B., et al.
Publicado: (2022)

Artificial intelligence-based (68)Ga-DOTATOC PET denoising for optimizing (68)Ge/(68)Ga generator use throughout its lifetime
por: Quak, Elske, et al.
Publicado: (2023)

[(68)Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning
por: Gehler, Barbara, et al.
Publicado: (2009)

Pindborg Tumor—An Uncommon Odontogenic Tumor Detected by 68Ga-DOTATOC
por: Herden, Anna, et al.
Publicado: (2022)

Diagnostic performance and impact on patient management of [(68)Ga]Ga-DOTA-TOC PET/CT in colorectal neuroendocrine tumors derived from hindgut
por: Delabie, Pierre, et al.
Publicado: (2022)

Same-day comparative protocol PET/CT-PET/MRI [(68) Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine
por: Prado-Wohlwend, Stefan, et al.
Publicado: (2023)

Initial Clinical Experience with (68)Ga-DOTA-NOC Prepared Using (68)Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based (68)Ge/(68)Ga Generator and Freeze-dried DOTA-NOC Kits
por: Chandra, Piyush, et al.
Publicado: (2017)

Role of Combined [(68)Ga]Ga-DOTA-SST Analogues and [(18)F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
por: Carideo, Luciano, et al.
Publicado: (2019)

Comparison of (68)Ga-DOTA-NaI(3)-Octreotide/tyr(3)-octreotate positron emission tomography/computed tomography and contrast-enhanced computed tomography in localization of tumors in multiple endocrine neoplasia 1 syndrome
por: Patil, Virendra A., et al.
Publicado: (2020)

Preparation and Biological Study of (68)Ga-DOTA-alendronate
por: Fakhari, Ashraf, et al.
Publicado: (2016)

Role of (68)Ga-DOTATOC PET/CT in the Evaluation of Primary Pulmonary Carcinoids
por: Jindal, Tarun, et al.
Publicado: (2010)

Evaluation of the Possible Utilization of (68)Ga-DOTATOC in Diagnosis of Adenocarcinoma Breast Cancer
por: Zolghadri, Samaneh, et al.
Publicado: (2018)

Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
por: Librizzi, Damiano, et al.
Publicado: (2023)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Functional Imaging of Pheochromocytoma with (68)Ga-DOTATOC and (68)C-HED in a Genetically Defined Rat Model of Multiple Endocrine Neoplasia
por: Miederer, Matthias, et al.
Publicado: (2011)

Splenosis Mimicking Relapse of a Neuroendocrine Tumor at Gallium-68-DOTATOC PET/CT
por: Treglia, Giorgio, et al.
Publicado: (2013)

Usefulness of (68)Ga-DOTATOC PET/CT to localize the culprit tumor inducing osteomalacia
por: Lee, Dong Yun, et al.
Publicado: (2021)

Prospective data-driven respiratory gating of [(68)Ga]Ga-DOTATOC PET/CT
por: Sigfridsson, Jonathan, et al.
Publicado: (2021)

Thyroid metastasis from lung carcinoid detected by (68)Ga-DOTATOC PET/CT
por: Albano, Domenico, et al.
Publicado: (2021)

(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
por: Boughdad, Sarah, et al.
Publicado: (2021)

Physiological Biodistribution of (68)Ga-DOTA-TATE in Normal Subjects
por: Özgüven, Salih, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iikorhkln3nnsg0mcrshmhjf2p